These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 9435450

  • 1. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 2. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 3. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [Abstract] [Full Text] [Related]

  • 4. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
    de Herder WW, Reijs AE, Feelders RA, van Aken MO, Krenning EP, Tanghe HL, van der Lely AJ, Kwekkeboom DJ.
    Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
    [Abstract] [Full Text] [Related]

  • 5. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [Abstract] [Full Text] [Related]

  • 6. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N, Rambaldi PF, Battista C, Ambrosio G, Cascini GL, Schillirò F, Mansi L.
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [Abstract] [Full Text] [Related]

  • 7. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W, Riedl M, Luger A, Czech T, Rössler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I, Brücke T.
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [Abstract] [Full Text] [Related]

  • 8. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW, Reijs AE, de Swart J, Kaandorp Y, Lamberts SW, Krenning EP, Kwekkeboom DJ.
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [Abstract] [Full Text] [Related]

  • 9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A, Landi ML, Marzullo P, Di Somma C, Pivonello R, Cerbone G, Lombardi G, Colao A.
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [Abstract] [Full Text] [Related]

  • 10. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U, Reichel M, Fett U, Saeger W, Quabbe HJ.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [Abstract] [Full Text] [Related]

  • 11. Long-term treatment with the dopamine agonist quinagolide of patients with clinically non-functioning pituitary adenoma.
    Nobels FR, de Herder WW, van den Brink WM, Kwekkeboom DJ, Hofland LJ, Zuyderwijk J, de Jong FH, Lamberts SW.
    Eur J Endocrinol; 2000 Nov; 143(5):615-21. PubMed ID: 11078985
    [Abstract] [Full Text] [Related]

  • 12. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G.
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [Abstract] [Full Text] [Related]

  • 13. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U, Bäder M, Hopfenmüller W, Saeger W, Quabbe HJ.
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [Abstract] [Full Text] [Related]

  • 14. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D'Angelo V, Scarabino T, Liuzzi A.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [Abstract] [Full Text] [Related]

  • 15. Diagnosis and treatment of pituitary adenomas.
    Chanson P, Salenave S.
    Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
    [Abstract] [Full Text] [Related]

  • 16. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
    Pirker W, Brücke T, Riedl M, Clodi M, Luger A, Asenbaum S, Podreka I, Deecke L.
    J Neural Transm Gen Sect; 1994 Dec; 97(3):235-44. PubMed ID: 7873131
    [Abstract] [Full Text] [Related]

  • 17. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R.
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [Abstract] [Full Text] [Related]

  • 18. [Treatment of pituitary adenomas].
    Mezosi E, Nemes O.
    Orv Hetil; 2009 Sep 27; 150(39):1803-10. PubMed ID: 19758960
    [Abstract] [Full Text] [Related]

  • 19. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy.
    Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW, Hofland LJ.
    J Clin Endocrinol Metab; 2008 Apr 27; 93(4):1412-7. PubMed ID: 18211974
    [Abstract] [Full Text] [Related]

  • 20. Effects of quinagolide (CV 205-502), a selective D2-agonist, on vascular reactivity in patients with a prolactin-secreting adenoma.
    Bodmer CW, Atkin SL, Savage MW, Masson EA, White MC.
    Clin Endocrinol (Oxf); 1995 Jul 27; 43(1):49-53. PubMed ID: 7641411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.